Testosterone-replacement therapy improves symptoms of metabolic syndrome

Hormone-replacement therapy significantly improved symptoms of metabolic syndrome associated with testosterone deficiency in men, a new study from Germany finds. The results to be presented at The Endocrine Society's 94th Annual Meeting in Houston.

Metabolic syndrome comprises a cluster of complications that can increase the risk of heart and blood-vessel disease as well as . These complications include , especially around the waist and torso, and abnormal concentrations of fat in the blood, known as lipids. In particular, patients with have high of the so-called bad fats, or triglycerides and low-density lipoproteins, and insufficient amounts of the healthy fats known as high-density lipoproteins. In addition, they often have high blood pressure and sugar, or glucose, levels.

Previous research has linked metabolic syndrome to testosterone deficiency, which can cause decreased muscle and , depression, low energy, and decreased sex drive and ability. In addition, testosterone deficiency is also associated with the individual symptoms of metabolic syndrome, even when they are present without the other complications.

"When indicated, testosterone treatment is both essential and safe in elderly patients with symptomatic late onset , or testosterone deficiency," said study lead author Aksam A. Yassin, M.D., Ph.D., Ed.D., chairman of the Institute of Urology & Andrology in Norderstedt-Hamburg, Germany. "Further analysis is needed to confirm if our findings are due to a direct effect of restoring physiologic testosterone levels."

Specifically, investigators found that the prevalence of metabolic syndrome dropped from 56 to 30 percent after 57 months of treatment with testosterone-replacement medication to regulate hormone levels. In addition, triglycerides, and levels of blood sugar and pressure significantly decreased, while the average waist circumference shrank by 11 centimeters.

Beginning in 2004, investigators collected data from 261 patients with late-onset hypogonadism, characterized by both low testosterone levels and sexual dysfunction, at three centers in Germany. Patients received 1,000 milligrams of a long-acting testosterone drug, called undecanoate, on the first day of the study, at week six, and then every three months. At each visit, patients underwent testing of hormone levels, blood-sugar and lipid concentrations, and blood pressure. Average follow-up was four and a quarter years.

"We hypothesized that long-term testosterone improves metabolic syndrome, and found that this intervention improved all three components of obesity, including waist circumference, weight, and body-mass index; diabetes control; poor lipids profile; and blood pressure," Yassin said.

To determine the presence of metabolic syndrome among study participants, investigators used the definition from the International Diabetes Federation. Participants were diagnosed with the syndrome if they displayed central-body obesity combined with two other risk factors. These included elevated triglycerides levels, decreased high-density lipoproteins, , and excessive blood-sugar concentrations.

add to favorites email to friend print save as pdf

Related Stories

Metabolic syndrome may cause kidney disease

Aug 19, 2011

Metabolic syndrome comprises a group of medical disorders that increase people's risk of diabetes, heart disease, stroke, and premature death when they occur together. A patient is diagnosed with the syndrome when he or she ...

Recommended for you

Medical charity warns India over patent rules

Jan 21, 2015

Doctors without Borders on Wednesday warned the Indian government not to bow to US pressure to amend patent regulations that allow millions access to affordable medicines, ahead of a visit by President Barack Obama.

Why are some generic drugs getting so expensive?

Jan 21, 2015

More than eight out of every 10 prescriptions dispensed in the US is generic. This growth is due to a large number of top-selling drugs going off patent over the past decade, as well as innovations in t ...

Supreme Court sides with Teva in drug dispute

Jan 20, 2015

The Supreme Court on Tuesday sided with Teva Pharmaceutical Industries Ltd. in the company's high-profile patent dispute with rival firms over the top-selling multiple sclerosis drug.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.